10 Results for "

subcutaneous injection

" in MedChemExpress (MCE) Product Catalog:
Products (10)

10 Results for "subcutaneous injection" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-14608R
CAS No.: 56-86-0
L-Glutamic acid (Standard) is the analytical standard of L-Glutamic acid. This product is intended for research and analytical applications. L-Glutamic acid is an excitatory amino acid neurotransmitter that acts as an agonist for all subtypes of glutamate receptors (metabolic rhodophylline, NMDA, and AMPA). L-Glutamic acid has an agonist effect on the release of DA from dopaminergic nerve endings. L-Glutamic acid can be used in the study of neurological diseases . IC50 & Target:DA . In Vitro: L-Glutamic acid (120, 500, 750, 1000 mg/dL) can reduce the harmful effect of lithium on the embryonic development of Xenopus Xenopus .
L-Glutamic acid (2, 5, 10, 20 mM, 24-48 h) can induce neuroexcitotoxicity in neuroblastoma .
In Vivo: L-Glutamic acid (3 g/kg, subcutaneous injection) can promote excitotoxic degeneration of retinal ganglion cells in mice .
L-Glutamic acid (750 mg/kg, intraperitoneal injection) can reduce and inhibit oxidative stress induced by chlorpyrifos (CPF) in rats .
loading...
    loading...
Cat. No.: HY-P991015
CAS No.: 2921676-04-0
Synonyms: JNJ-78278343; KLCB-245

Target:  

CD3

Research Areas:  

Cancer

Pasritamig (JNJ-78278343; KLCB-245) is a bispecific T-cell engager (BiTE) that targets the complex of human kallikrein KLK2 and CD3 receptor. Pasritamig redirects the cytotoxicity of T cells to KLK2-expressing tumor cells and induces T cell-mediated lysis of KLK2-expressing prostate cancer cells. Administered via subcutaneous injection, subcutaneous infusion or intravenous infusion, Pasritamig exhibits antitumor activity against metastatic castration-resistant prostate cancer. Pasritamig has a safety profile with an extremely low incidence of cytokine release syndrome and can be safely administered in an outpatient setting. Pasritamig is applicable to the research of metastatic castration-resistant prostate cancer .
loading...
    loading...
Cat. No.: HY-145476
CAS No.: 887407-16-1
Synonyms: N-NAT; N'-Nitrosoanatabine
Target:  

Others

Research Areas:  

Others

N-Nitrosoanatabine (N-NAT; N'-Nitrosoanatabine) is a tobacco-specific nitrosamine that exists in tobacco, tobacco products and e-cigarettes .
loading...
    loading...
Cat. No.: HY-W021450A
CAS No.: 100929-81-5
Research Areas:  

Neurological Disease

DL-Fluorocitric acid barium is a glial cell metabolic inhibitor. DL-Fluorocitric acid barium inhibits mechanical hyperalgesia induced by subcutaneous injection of complete Freund's adjuvant in rats. DL-Fluorocitric acid barium inhibits nociceptive behaviors induced by Histamine (HY-B1204) in mice and blocks the phosphorylation of the NMDA receptor NR1 subunit in the lumbar spinal cord of mice. DL-Fluorocitric acid (barium) can be used in the research of mechanical hyperalgesia and nociceptive pain .
loading...
    loading...
Cat. No.: HY-W751579
CAS No.: 234096-34-5
Target:  

Bacterial Antibiotic

Research Areas:  

Infection

Cefovecin is a third-generation cephalosporin antibiotic. Cefovecin's most notable characteristic is its extremely long-lasting effect; a single subcutaneous injection can maintain an effective therapeutic concentration in tissues for up to 14 days. Cefovecin is used in research on bacterial infections in dogs and cats .
loading...
    loading...
Cat. No.: HY-15616
CAS No.: 457893-92-4
Target:  

Melanocortin Receptor

Research Areas:  

Cancer

BMS-470539 is a synthetic MC-1R agonist with potent anti-inflammatory properties. BMS-470539 selectively activates human and murine MC-1R with EC50 values ??of 16.8 nM and 11.6 nM, respectively. In vitro studies have shown that BMS-470539 is able to dose-dependently inhibit TNF-alpha-induced NF-kB activation in human melanoma cells expressing MC-1R. In vivo, subcutaneous injection of BMS-470539 into BALB/c mice effectively inhibited LPS-induced TNF-alpha production with an ED50 of approximately 10 μmol/kg and a pharmacodynamic half-life of approximately 8 hours. It also significantly reduced leukocyte infiltration in a lung inflammation model and attenuated paw swelling in a delayed-type hypersensitivity model, highlighting its efficacy as an anti-inflammatory agent through MC-1R modulation .
loading...
    loading...
Cat. No.: HY-W714505
CAS No.: 63886-94-2
Target:  

Opioid Receptor

Research Areas:  

Neurological Disease

AH 7563 structurally belongs to the opioid compounds and exhibits analgesic activity. In the phenylquinone test and hot plate test, the ED50 of AH 7563 for analgesia in mice were 15.3 mg/kg (orally) and 15.5 mg/kg (subcutaneous injection), respectively .
loading...
    loading...
Cat. No.: HY-P0037
CAS No.: 136208-71-4
Synonyms: Org 30850ANT
Target:  

GnRH Receptor

Research Areas:  

Endocrinology

Org-30850 is a potent LHRH antagonist designed for treating hormone-dependent disorders. In animal studies, a single subcutaneous dose effectively inhibited ovulation in rats and significantly reduced testosterone levels in male rats for up to 48 hours post-administration. Daily doses of Org-30850 in female rats suppressed estrous cycles, decreased uterine and ovarian weights, and lowered estradiol and FSH serum levels. In male rats, prolonged treatment resulted in reversible reductions in gonadal function and testosterone levels, with almost complete recovery observed after cessation of treatment. Unlike comparable LHRH antagonists, Org-30850 exhibited minimal injection site irritation and no edematous reactions, suggesting a more favorable therapeutic profile .
loading...
    loading...
Cat. No.: HY-19873
CAS No.: 925438-34-2
Target:  

Photosensitizer

Research Areas:  

Cancer

SL-052 is a hypocrellin-based photosensitizer that has recently shown promising results in clinical and preclinical testing for cancer photodynamic therapy (PDT). SL-052 is encapsulated in biodegradable polylactic-co-glycolic acid (PLGA) polymer nanoparticles optimized using single emulsion solvent evaporation technology. The SL-052-PLGA nanoparticles were more effective in PDT treatment of subcutaneous SCCVII squamous cell carcinoma compared to polyvinylpyrrolidone (PVP)-based and standard liposomal SL-052 formulations. A longer time interval between drug injection and tumor illumination can improve tumor cure rates, and SL-052-PLGA nanoparticles showed the best therapeutic effect among all SL-052 formulations.
loading...
    loading...
Cat. No.: HY-118647
CAS No.: 584-69-0
Synonyms: Etisul
Target:  

Bacterial

Research Areas:  

Infection

Ditophal is an orally active thiol ester anti-tuberculosis and anti-leprosy agent. Ditophal combats Mycobacterium tuberculosis infections in subcutaneous and intracerebral sites in guinea pigs, including isoniazid (HY-B0329)-resistant strains. Ditophal alters the staining characteristics of Mycobacterium leprae and reduces the bacterial index of leprosy. Ditophal causes ulcers at the injection site when administered subcutaneously to guinea pigs at high doses. Ditophal can be used in the research of tuberculosis and leprosy .
loading...
    loading...